Equities

Actuate Therapeutics Inc

ACTU:NMQ

Actuate Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)9.02
  • Today's Change0.05 / 0.56%
  • Shares traded75.35k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. Its lead program, Elraglusib Injection, is an intravenous solution of elraglusib for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib Injection has been evaluated in a Phase I dose escalation study (Actuate-1801 Part 1) in 238 adult patients. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

  • Revenue in USD (TTM)--
  • Net income in USD--
  • Incorporated2015
  • Employees11.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Repare Therapeutics Inc66.52m-84.05m157.29m179.00--0.899--2.36-2.00-2.001.564.120.270--3.95371,642.50-34.11-23.40-40.73-26.37-----126.34-162.76----0.00---61.21---222.91--27.16--
Vaxart Inc13.93m-75.66m157.80m109.00--1.97--11.33-0.4707-0.47070.08610.35180.1178--5.80127,779.80-64.01-49.60-73.18-54.86-----543.21-1,398.00---226.730.0507--6,796.2612.1523.47--21.49--
Adverum Biotechnologies Inc1.00m-94.11m161.43m121.00--1.12--161.43-6.03-6.030.05856.930.0046----8,264.46-43.66-36.39-50.24-39.04-----9,411.10-5,279.60----0.00----17.4324.18---0.0247--
Puma Biotechnology Inc219.14m8.72m161.85m185.0018.033.307.980.73860.1830.1834.561.001.087.077.381,184,557.004.30-12.217.24-20.5373.0878.783.98-11.791.231.990.6474--3.34-1.251,079,450.00--83.41--
PepGen Inc0.00-87.23m162.62m64.00--1.18-----2.98-2.980.004.220.00----0.00-52.16---58.79--------------0.00-------13.78------
Skye Bioscience Inc0.00-42.29m166.86m11.00--2.12-----3.91-3.910.002.590.00----0.00-94.50-232.67-129.40-------------323.100.0626-------93.23--23.38--
Actuate Therapeutics Inc-100.00bn-100.00bn175.20m11.00---------------1.05-------------------------------------22.74------
Cardiff Oncology Inc689.00k-43.01m176.92m31.00--3.41--256.78-0.9493-0.94930.01521.010.0091--1.6922,225.81-56.80-31.24-66.22-33.56-----6,238.17-7,819.23----0.00--26.425.22-7.07--157.91--
Lineage Cell Therapeutics Inc6.19m-24.19m178.26m75.00--2.61--28.82-0.1342-0.13420.03430.36170.0577--18.2582,480.00-22.57-19.53-26.03-22.5990.8389.13-391.25-370.88----0.0017---39.1612.3918.22---27.16--
Galectin Therapeutics Inc0.00-48.03m179.98m14.00---------0.7831-0.78310.00-1.320.00----0.00-185.54-92.08-382.33-121.97-----------8.598.29-------15.26------
DiaMedica Therapeutics Inc0.00-19.90m180.82m18.00--3.38-----0.5238-0.52380.001.250.00----0.00-33.49-45.38-34.98-48.24------------0.0006-------41.72---13.65--
Greenwich Lifesciences Inc0.00-10.22m184.81m3.00--31.27-----0.7942-0.79420.000.44960.00----0.00-112.41-36.43-123.67-38.31------------0.00-------13.63------
Aclaris Therapeutics Inc27.08m-37.00m187.86m91.00--1.44--6.94-0.5198-0.51980.38061.820.1352--78.61297,582.40-18.47-47.29-20.87-53.8753.5344.00-136.65-549.18----0.00--5.0338.41-1.81---0.703--
Sagimet Biosciences Inc2.00m-29.25m188.34m10.00--1.02--94.17-1.18-1.180.0785.740.019----200,000.00-27.79---29.32-------1,462.55------0.00------8.60------
Inhibikase Therapeutics Inc79.57k-18.38m188.77m8.00--4.06--2,372.40-2.93-2.930.01260.70630.0051----9,946.25-117.93-66.49-148.63-85.55-----23,102.16-1,139.14----0.00--111.03-42.21-5.40------
Black Diamond Therapeutics Inc0.00-73.10m191.26m54.00--1.96-----1.36-1.360.001.720.00----0.00-47.12-40.29-53.28-43.29------------0.00------9.57---15.37--
Data as of Nov 12 2024. Currency figures normalised to Actuate Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

0.06%Per cent of shares held by top holders
HolderShares% Held
KG&L Capital Management LLCas of 30 Sep 202412.00k0.06%
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.